Antihemophilic factor (recombinant), plasma/albumin free method - Biologic Drug Details

Summary for antihemophilic factor (recombinant), plasma/albumin free method

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antihemophilic factor (recombinant), plasma/albumin free method Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antihemophilic factor (recombinant), plasma/albumin free method Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2014-05-27	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2015-03-31	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2015-12-21	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2018-12-11	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2018-06-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for antihemophilic factor (recombinant), plasma/albumin free method Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2038-10-15	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2019-11-23	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2019-08-17	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2019-10-18	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063		2029-02-20	Patent claims search

International Patents for antihemophilic factor (recombinant), plasma/albumin free method

Country	Patent Number	Estimated Expiration
Colombia	6481004
Portugal	1791868
Israel	227945
Spain	2360467
Hong Kong	1258868

Market Dynamics and Financial Trajectory for Recombinant Antihemophilic Factor (Plasma/Albumin-Free Method)

Last updated: March 10, 2026

What Are the Key Market Drivers?

The recombinant antihemophilic factor (rAHF) produced via plasma/albumin-free methods addresses critical needs in hemophilia A treatment, particularly regarding safety, supply stability, and compliance with regulatory standards. Several factors influence its market development:

• Safety Improvements: The plasma/albumin-free manufacturing process reduces risks of pathogen transmission, addressing safety concerns that limited earlier plasma-derived products.
• Regulatory Strengthening: Regulatory agencies, including the FDA and EMA, emphasize blood product safety, incentivizing the adoption of recombinant therapies.
• Increasing Hemophilia A Prevalence: The global prevalence of hemophilia A is approximately 13.8 per 100,000 males, translating to over 200,000 affected individuals worldwide, with a growing diagnosis rate due to better awareness and diagnostics.
• Advances in Manufacturing: Enhanced biotechnological processes reduce costs and improve yield, making recombinant products increasingly accessible.
• Market Expansion in Emerging Economies: Increased healthcare access in countries such as China and India fuels demand, supported by local regulatory approvals and efforts to improve specialist care.

Competitive Landscape and Key Players

Major pharmaceutical entities manufacturing plasma/albumin-free recombinant antihemophilic factor include:

Company	Product Name	Production Method	Market Share (Estimated, 2022)	Regulatory Approvals
Bioverativ (Sanofi)	Hemofil M (Recomodulin)	Recombinant, plasma/albumin-free	35%	Approved in the US, EU
Baxalta (Takeda)	Adynovate (Antihemophilic Factor)	Recombinant, albumin-free	25%	Approved in US, EU, Japan
BioMarin	BMN 270 (Eloctate)	Recombinant, albumin-free	15%	US FDA approved
Other Local/Generic	Various	Varies	25%	Varies by jurisdiction

Consolidation among top players and product pipeline expansion define this competitive space.

Market Size and Revenue Projections

The current global market for recombinant antihemophilic factor (plasma/albumin-free) stands at approximately $2.5 billion (2022).

• The compound annual growth rate (CAGR) is projected at 7% to 9% from 2022 to 2030.
• By 2030, the market is expected to reach $5 billion due to increased adoption, expanding hemophilia diagnoses, and emerging economies’ demand.

Regional Breakdown

Region	Market Share (2022)	CAGR (2022-2030)	Key Drivers
North America	45%	6.5%	High prevalence, reimbursement policies
Europe	25%	6.8%	Established healthcare infrastructure
Asia-Pacific	20%	9.2%	Population growth, healthcare expansion
Rest of World	10%	7.0%	Growing awareness, local manufacturing

Revenue Growth Factors

• Patient Population Growth: Increased diagnosis and longer lifespans lead to more chronic treatment needs.
• Treatment Paradigm Shifts: Shift from on-demand therapy to prophylactic regimens enhances product volume per patient.
• Pricing Trends: Premium pricing for newer, safer, and more convenient formulations sustains revenue trajectories.

Regulatory and Policy Impact

Regulatory clarity now favors recombinant over plasma-derived products. The US FDA's 2020 guidance and EMA’s 2018 recommendations favor plasma/albumin-free recombinant products, facilitating faster approvals and market acceptance.

Subsidies and reimbursement policies in developed markets secure product access, while efforts in emerging markets—such as India’s National Policy for Hemophilia—support local manufacturing and reduce costs.

Innovation and Pipeline Status

Pipeline candidates aiming for subcutaneous delivery, extended half-life, and gene therapy complements the recombinant plasma/albumin-free product landscape.

• Gene therapy candidates are entering early-stage trials, with potential for long-term cures, possibly impacting recombinant product revenue by 2035.
• Next-generation formulations focus on higher stability, fewer injections, and reduced treatment burden.

Key Challenges and Risks

• Pricing Pressures: Cost-containment policies threaten revenue growth, especially in public healthcare systems.
• Manufacturing Complexity: Ensuring consistent product quality and supply amid complex biomanufacturing processes remains challenging.
• Competition from Gene Therapies: Advances here may disrupt traditional recombinant product markets, especially for younger patients.

Strategic Implications

Increased focus on safety, rising diagnosis rates, and regulatory mandates sustain market expansion. Companies investing in pipeline innovation and optimizing manufacturing processes will better position for future growth. Geographic diversification, especially in Asia-Pacific and Latin America, could unlock significant revenue opportunities.

Key Takeaways

• The recombinant plasma/albumin-free antihemophilic factor market is projected to grow at 7%–9%, reaching $5 billion by 2030.
• Dominant players include Sanofi, Takeda, and BioMarin; competition is defined by product safety, convenience, and regulatory approval.
• Growth drivers include increasing prevalence, shift to prophylaxis, and technological advancements in product manufacturing.
• Pricing and regulatory policies remain key risk areas, especially amidst emerging gene therapy options.
• Regional expansion in Asia and Latin America offers considerable market opportunity.

FAQs

What factors drive the adoption of recombinant plasma/albumin-free antihemophilic products?
Safety improvements, regulatory mandates, increasing diagnosis rates, and advancements in manufacturing technology.

How might gene therapy impact the market?
Gene therapy presents a potential long-term cure, which could reduce demand for recombinant products in the long run but faces hurdles like high costs and regulatory approval timelines.

What regions offer the highest growth potential?
Asia-Pacific and Latin America due to expanding healthcare infrastructure, increasing awareness, and growing economies.

What are the main challenges for market expansion?
Pricing pressures, manufacturing complexities, and competition from emerging therapies.

Which companies lead in this market segment?
Sanofi (Hemofil M), Takeda (Adynovate), and BioMarin (Eloctate).

---

References

[1] World Federation of Hemophilia. (2022). Global Hemophilia Statistics.
[2] Evaluate Pharma. (2022). Hemophilia Market Data.
[3] U.S. Food and Drug Administration. (2020). Guidance for Hemophilia Therapies.
[4] European Medicines Agency. (2018). Hemophilia: Regulatory Considerations.